AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6758833 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 30 mg daily given orally for two weeks
Number of subjects: 10
Study 6758833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31464286 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognan (citicoline) 500 mg (5 ml) orally for 30 days
Number of subjects: 38
Study 31464286 — intervention group
Group type: COMPARATOR
Intervention: No drug therapy (Control)
Number of subjects: 38
Study 30255345 — intervention group
Group type: EXPERIMENTAL
Intervention: Running locked 3-0 delayed absorbable suture (Group 2)
Number of subjects: 90
Study 30255345 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal interrupted 3-0 delayed absorbable sutures (Group 1)
Number of subjects: 90
Study 30255345 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 26651260 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid (ALA) 600 mg qd
Number of subjects: 460
Study 26651260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study 24216721 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day) and cilostazol (200 mg/day) with behavioral modifications
Number of subjects: 34
Study 24216721 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg/day) with behavioral modifications (control group)
Number of subjects: 34
Study 24216721 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol and cilostazol treatment
Number of subjects: 34
Study 24216721 — intervention group
Group type: COMPARATOR
Intervention: Aspirin treatment
Number of subjects: 34
Study 22898703 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 weeks of pegylated interferon plus ribavirin (n=168)
Number of subjects: 335
Study 22898703 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 weeks of pegylated interferon plus ribavirin (n=167)
Number of subjects: 335
Study 22898703 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 72-week vs 48-week treatment in non-week-8 viral response patients
Number of subjects: 335
Study 20052732 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Education
Number of subjects: 369
Study 20052732 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 369
Study 20052732 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one education
Number of subjects: 369
Study 20052732 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing out-of-pocket costs
Number of subjects: 369
Study 17392464 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 0
Study 17392464 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study 17392464 — intervention group
Group type: COMPARATOR
Intervention: No patch (matched nonsmokers)
Number of subjects: 0
Study 15971426 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-steroid-saline mixture as contrast medium
Number of subjects: 0
Study 12410357 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid eversion endarterectomy (CEE)
Number of subjects: 310
Study 12410357 — intervention group
Group type: COMPARATOR
Intervention: Traditional CEA with patching (CEAP)
Number of subjects: 310
Study 10637949 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised treatment within 3 hours
Number of subjects: 1631
Study 10637949 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised treatment within 6 hours
Number of subjects: 1631
Study 10637949 — intervention group
Group type: EXPERIMENTAL
Intervention: Death or dependency at 6 months
Number of subjects: 1631
Study 10637949 — intervention group
Group type: EXPERIMENTAL
Intervention: Total anterior circulation infarcts
Number of subjects: 1631
Study 10637949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunar strokes
Number of subjects: 1631
Study 7737560 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg daily for one week
Number of subjects: 32
Study 7737560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2036277 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg
Number of subjects: 150
Study 2036277 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 2 mg
Number of subjects: 150
Study 2036277 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 4 mg
Number of subjects: 150
Study 2036277 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 150
Study 2036277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 7131544 — intervention group
Group type: EXPERIMENTAL
Intervention: High feedback ultrasound (N = 67)
Number of subjects: 129
Study 7131544 — intervention group
Group type: EXPERIMENTAL
Intervention: Low feedback ultrasound (N = 62)
Number of subjects: 129
Study 7131544 — intervention group
Group type: COMPARATOR
Intervention: Wait control group
Number of subjects: 129
Study 29982720 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment adjustment not in agreement with TTT strategy
Number of subjects: 74
Study 29982720 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 74
Study 29982720 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated disease activity measure despite no objective evidence of active RA
Number of subjects: 74
Study 26642907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic-guided warfarin dosing algorithm
Number of subjects: 1015
Study 26642907 — intervention group
Group type: COMPARATOR
Intervention: Clinically-guided warfarin dosing algorithm
Number of subjects: 1015
Study 26642907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (pharmacogenetic and clinical)
Number of subjects: 1015
Study 25685772 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis and counseling to adhere to it
Number of subjects: 341
Study 23006426 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVE memory training intervention
Number of subjects: 1401
Study 23006426 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 1401
Study 20950379 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 5269
Study 20950379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5269
Study 18181162 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioguided occult lesion localization (ROLL)
Number of subjects: 100
Study 18181162 — intervention group
Group type: COMPARATOR
Intervention: Wire localization (WL)
Number of subjects: 100
Study 16804099 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 15
Study 16804099 — intervention group
Group type: COMPARATOR
Intervention: Codeine phosphate 7‐15 mg 3‐4 times daily
Number of subjects: 15
Study 12631126 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (E) 600 mg/day PO for seven days
Number of subjects: 24
Study 12631126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12631126 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (E)
Number of subjects: 24
Study 10672218 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous retraction force averaging 18 g
Number of subjects: 7
Study 10672218 — intervention group
Group type: COMPARATOR
Intervention: Continuous retraction force averaging 60 g
Number of subjects: 7
Study 9032777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg/h cortisol infusion
Number of subjects: 32
Study 9032777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg/h cortisol infusion
Number of subjects: 32
Study 9032777 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (placebo tablets and normal saline infusion)
Number of subjects: 32
Study 8195849 — intervention group
Group type: EXPERIMENTAL
Intervention: brodimoprim
Number of subjects: 74
Study 8195849 — intervention group
Group type: COMPARATOR
Intervention: roxithromycin
Number of subjects: 74
Study 3896283 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (5 mg h-1 for 3 h via intravenous infusion)
Number of subjects: 12
Study 3896283 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (30 mg three times daily for 1 week)
Number of subjects: 12
Study 3896283 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group in the second study)
Number of subjects: 12
Study 30087193 — intervention group
Group type: EXPERIMENTAL
Intervention: Large spacer plus pMDI (pressurized metered-dose inhaler)
Number of subjects: 12
Study 30087193 — intervention group
Group type: COMPARATOR
Intervention: T-piece
Number of subjects: 12
Study 30087193 — intervention group
Group type: COMPARATOR
Intervention: Large spacer
Number of subjects: 12
Study 30087193 — intervention group
Group type: EXPERIMENTAL
Intervention: Large spacer plus pMDI
Number of subjects: 12
Study 27687343 — intervention group
Group type: COMPARATOR
Intervention: High dose of remifentanil (HR) group
Number of subjects: 75
Study 27687343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of remifentanil (LR) group
Number of subjects: 75
Study 27687343 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol combined with remifentanil (BR) group
Number of subjects: 75
Study 27687343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of butorphanol (BR group)
Number of subjects: 75
Study 24048161 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOFlipid emulsion for 7 days
Number of subjects: 34
Study 24048161 — intervention group
Group type: COMPARATOR
Intervention: Clinoleic emulsion for 7 days
Number of subjects: 34
Study 23698697 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling session on alcohol risk reduction
Number of subjects: 147
Study 23698697 — intervention group
Group type: COMPARATOR
Intervention: Health education leaflet
Number of subjects: 147
Study 20441727 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 336
Study 20441727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 17970761 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg)
Number of subjects: 11
Study 17970761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 16652312 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved environmental cleaning measures during period 2
Number of subjects: 748
Study 16652312 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention (washout period 3)
Number of subjects: 748
Study 16652312 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal hand hygiene intervention (period 4)
Number of subjects: 748
Study 16652312 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental cleaning rates
Number of subjects: 748
Study 16652312 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene adherence
Number of subjects: 748
Study 16652312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model for VRE acquisition
Number of subjects: 748
Study 12969704 — intervention group
Group type: EXPERIMENTAL
Intervention: Single IUI
Number of subjects: 110
Study 12969704 — intervention group
Group type: EXPERIMENTAL
Intervention: Double IUI
Number of subjects: 110
Study 10212110 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Shuttle Test (MST)
Number of subjects: 20
Study 10212110 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression equation for VO2peak based on MST distance
Number of subjects: 20
Study 8942357 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy-protein supplement given immediately after rehydration
Number of subjects: 34
Study 8942357 — intervention group
Group type: COMPARATOR
Intervention: High-energy-protein supplement given 2 weeks after presentation
Number of subjects: 34
Study 2057036 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-hour nicotine patch (15 +/- 3.5 mg of nicotine in 16 hours)
Number of subjects: 289
Study 2057036 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 289
Study 3914473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 gram preoperative dose)
Number of subjects: 57
Study 3914473 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (2 gram preoperative dose and four 2 gram postoperative doses)
Number of subjects: 57
Study 31733770 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sphygmomanometer Test (MST) with fixed stabilization
Number of subjects: 59
Study 28125252 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 300
Study 28125252 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopharmacological treatment
Number of subjects: 300
Study 28125252 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjusted NEO-PI-R scales
Number of subjects: 300
Study 25956151 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing retraining (DBR) intervention over 8 weeks with follow-up at 5 months
Number of subjects: 36
Study 25956151 — intervention group
Group type: COMPARATOR
Intervention: Attention control group receiving general health information
Number of subjects: 36
Study 24506529 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA™)
Number of subjects: 320
Study 24506529 — intervention group
Group type: COMPARATOR
Intervention: Thermal balloon ablation (TBall)
Number of subjects: 320
Study 22344555 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod 800 mg
Number of subjects: 20
Study 20100756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (core temperatures of 35.5 degrees C, 34.5 degrees C, and 33.5 degrees C) for 48 hours
Number of subjects: 15
Study 20100756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (cooling group)
Number of subjects: 15
Study 20100756 — intervention group
Group type: COMPARATOR
Intervention: Noncooled group (control)
Number of subjects: 15
Study 17659006 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm monochromatic excimer light (MEL)
Number of subjects: 21
Study 17659006 — intervention group
Group type: COMPARATOR
Intervention: Narrowband UVB phototherapy (NB‐UVB)
Number of subjects: 21
Study 16185216 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-Day Plan (FDP) - a behavioural group-based treatment programme involving five consecutive evening sessions.
Number of subjects: 228
Study 16185216 — intervention group
Group type: COMPARATOR
Intervention: Control group - a single session discussing the health effects of smoking.
Number of subjects: 228
Study 12610193 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 578
Study 12610193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 578
Study 14564595 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (30 microg.kg(‐1))
Number of subjects: 60
Study 14564595 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (1.5 mg.kg(‐1))
Number of subjects: 60
Study 8800982 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ST segment monitoring for 48 hours
Number of subjects: 212
Study 8800982 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission ECG ST depression
Number of subjects: 212
Study 8800982 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal admission ECG
Number of subjects: 212
Study 8800982 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance beta blocker treatment
Number of subjects: 212
Study 8800982 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient ischaemia
Number of subjects: 212
Study 1671795 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol palmitate (300,000 IU daily for at least 12 months)
Number of subjects: 283
Study 1671795 — intervention group
Group type: COMPARATOR
Intervention: Standard observation (control group)
Number of subjects: 283
Study 1671795 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol palmitate
Number of subjects: 283
Study 6361986 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (DS) 2-3 mg/kg/day
Number of subjects: 45
Study 6361986 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 50-100 mg/kg/day
Number of subjects: 45
Study 6361986 — intervention group
Group type: COMPARATOR
Intervention: Placebo matching diclofenac
Number of subjects: 45
Study 6361986 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (DS)
Number of subjects: 45
Study 6361986 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 45
Study 29607845 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio aids + Braille
Number of subjects: 60
Study 29607845 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio aids + Tactile models
Number of subjects: 60
Study 29607845 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio aids + Braille + Tactile models
Number of subjects: 60
Study 29607845 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 27560769 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 66
Study 27560769 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 66
Study 25455853 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI)
Number of subjects: 16
Study 25455853 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus (IB)
Number of subjects: 16
Study 25455853 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CI and IB
Number of subjects: 16
Study 23991670 — intervention group
Group type: EXPERIMENTAL
Intervention: GW870086 (1 mg, once-daily)
Number of subjects: 36
Study 23991670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 21632199 — intervention group
Group type: EXPERIMENTAL
Intervention: NADA Auricular Acupuncture (AA)
Number of subjects: 101
Study 21632199 — intervention group
Group type: COMPARATOR
Intervention: Sham Auricular Acupuncture (AA)
Number of subjects: 101
Study 21632199 — intervention group
Group type: COMPARATOR
Intervention: Treatment setting control
Number of subjects: 101
Study 18501783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (160-mg/d tablet)
Number of subjects: 24
Study 17040926 — intervention group
Group type: EXPERIMENTAL
Intervention: Self management programme for arthritis and an education booklet
Number of subjects: 812
Study 17040926 — intervention group
Group type: COMPARATOR
Intervention: Education booklet alone
Number of subjects: 812
Study 14643944 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0
Study 14643944 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM
Number of subjects: 0
Study 14643944 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 14643944 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.05% blood alcohol level)
Number of subjects: 0
Study 14643944 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-drug-using participants)
Number of subjects: 0
Study 11918092 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 0
Study 11918092 — intervention group
Group type: EXPERIMENTAL
Intervention: Overbreathe under isocapnic conditions
Number of subjects: 0
Study 11918092 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral movement
Number of subjects: 0
Study 11918092 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 8927195 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional management training
Number of subjects: 16
Study 8927195 — intervention group
Group type: COMPARATOR
Intervention: Anti-stress therapy
Number of subjects: 16
Study 1624155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride capsules
Number of subjects: 6
Study 1624155 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose electrolyte solution
Number of subjects: 6
Study 1624155 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymer solution
Number of subjects: 6
Study 1624155 — intervention group
Group type: COMPARATOR
Intervention: No added salt (control)
Number of subjects: 6
Study 6152088 — intervention group
Group type: EXPERIMENTAL
Intervention: sultosilic acid piperazine salt (A‐585)
Number of subjects: 20
Study 6152088 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 20
Study 29405548 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuffle stimulation
Number of subjects: 12
Study 29405548 — intervention group
Group type: COMPARATOR
Intervention: Conventional stimulation
Number of subjects: 12
Study 27324280 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (4 mg per infusion for adults >25 years; 0.05 mg/kg for first two infusions and 4 mg for remaining eight infusions for patients aged 18-25 years; 0.05 mg/kg per infusion for younger patients) combined with standard chemotherapy.
Number of subjects: 318
Study 27324280 — intervention group
Group type: COMPARATOR
Intervention: Control group (chemotherapy alone).
Number of subjects: 318
Study 24211863 — intervention group
Group type: COMPARATOR
Intervention: Conventional implantation (atelocollagen gel at room temperature for 15 minutes)
Number of subjects: 27
Study 24211863 — intervention group
Group type: EXPERIMENTAL
Intervention: Preheating (atelocollagen warmed at 41 C for 8 minutes)
Number of subjects: 27
Study 23764081 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic urethral lift
Number of subjects: 206
Study 23764081 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 206
Study 19740072 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 40
Study 19740072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18046340 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal amnioinfusion (TA) with normal saline solution
Number of subjects: 44
Study 18046340 — intervention group
Group type: COMPARATOR
Intervention: Control group (those who declined TA)
Number of subjects: 44
Study 16388054 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock absorbing insoles (Sorbothane or Poron)
Number of subjects: 1205
Study 16388054 — intervention group
Group type: COMPARATOR
Intervention: Non-shock absorbing insoles (Saran)
Number of subjects: 1205
Study 16388054 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbothane insoles
Number of subjects: 1205
Study 16388054 — intervention group
Group type: EXPERIMENTAL
Intervention: Poron insoles
Number of subjects: 1205
Study 12077570 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine treatment
Number of subjects: 49